Genetically Modified Model Report on Toxicology Studies of Dicyclohexylcarbodiimide and Carcinogenicity Study of Dicyclohexylcarbodiimide

Dicyclohexylcarbodiimide is used in industry as a stabilizing agent, coupling agent, & condensing agent. Its widespread use during protein synthesis in the recombinant DNA industry & in the synthesis of polypeptides in the chemical & pharmaceutical industries provides an increasing potential for low-level human exposure. Dicyclohexylcarbodiimide was nominated for study as a key representative of the carbodiimide chemical class because of its acute toxicity & the absence of data on potential health effects. Under the conditions of this 27-week dermal study, there was no evidence of carcinogenic activity of dicyclohexylcarbodiimide in female p53 haplo-insufficient mice administered 0.75, 3, 6, or 12 mg/kg in ethanol. Female Tg.AC hemizygous mice dermally dosed with dicyclohexylcarbodiimide for 20 weeks had significantly increased incidences of squamous cell papilloma of the skin at the site of application. Non-neoplastic lesions noted at the site of application included chronic active inflammation & epidermal hyperplasia in female p53 haplo-insufficient mice & female Tg.AC hemizygous mice. Illus.Chabra, R. S. is the author of 'Genetically Modified Model Report on Toxicology Studies of Dicyclohexylcarbodiimide and Carcinogenicity Study of Dicyclohexylcarbodiimide', published 2008 under ISBN 9781422319789 and ISBN 1422319784.